Anixa BiosciencesANIX -4.52%27 Return-on-Tangible-Asset is -66.87% as of Apr. 2026. GuruFocus rates ANIX with a GF Score™ of 27/100. The stock has 3 warning signs investors should review. Among 1,413 Biotechnology companies, Anixa Biosciences ranks worse than 66.45% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Anixa Biosciences's annualizedNet Income for the quarter that ended in Apr. 2026 was $-10.06 Mil. Anixa Biosciences's average total tangible assets for the quarter that ended in Apr. 2026 was $15.05 Mil. Therefore, Anixa Biosciences's annualized Return-on-Tangible-Asset for the quarter that ended in Apr. 2026 was -66.87%.
The historical rank and industry rank for Anixa Biosciences's Return-on-Tangible-Asset or its related term are showing as below:
ANIX'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -220.81 Med: -76.16 Max: -35.08
Current: -62.09
During the past 13 years, Anixa Biosciences's highest Return-on-Tangible-Asset was -35.08%. The lowest was -220.81%. And the median was -76.16%.
ANIX's Return-on-Tangible-Asset is ranked worse than 66.45% of 1413
companies
in the Biotechnology industry
Industry Median: -35.77
vs ANIX: -62.09
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Anixa Biosciences Return-on-Tangible-Asset Related Terms
Anixa Biosciences Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Anixa Biosciences's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANIX vs BMEA, PMN, ATRA: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Anixa Biosciences's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anixa Biosciences Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Anixa Biosciences's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Apr. 2026) net income data.
What does a Return-on-Tangible-Asset of -66.87% mean?
Anixa Biosciences (ANIX) has a Return-on-Tangible-Asset of -66.87% as of Apr. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Anixa Biosciences and its competitors. According to the industry distribution chart, Anixa Biosciences ranks #939 out of 1413 companies in the Biotechnology industry, placing it in the top 66.5%.
Is Anixa Biosciences' Return-on-Tangible-Asset too high?
Anixa Biosciences' current Return-on-Tangible-Asset is -66.87%. Based on the distribution chart, Anixa Biosciences ranks #939 out of 1413 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Anixa Biosciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' Return-on-Tangible-Asset compare to BMEA and PMN?
According to the Biotechnology industry distribution chart, Anixa Biosciences ranks #939 out of 1413 companies for Return-on-Tangible-Asset. This places Anixa Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Anixa Biosciences and its competitors. Anixa Biosciences's current Return-on-Tangible-Asset is -66.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (ANIX) has a current Return-on-Tangible-Asset of -66.87%. The current Return-on-Tangible-Asset is -66.87%. Anixa Biosciences' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Anixa Biosciences (ANIX), the current Return-on-Tangible-Asset is -66.87% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
27GF Score
Get the complete analysis for ANIX
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANIX has been successfully added to your 
